| 查看: 1587 | 回复: 5 | ||||
| 当前只显示满足指定条件的回帖，点击这里查看本话题的所有回帖 | ||||
[交流]
【求助】AC2993一期、二期临床研究申报资料
|
||||
| 跪求AC2993一期和二期临床研究的申报资料，现要翻译临床研究有关增大剂量的副反应、耐受性、安全性等的相关资料，可惜没有电子版，本人英文能力有限，翻译起来比较困难，最好有中文版的，不胜感激！ |
回复此楼» 收录本帖的淘帖专辑推荐
 work or phd? |
» 猜你喜欢
药学专硕调剂
已经有2人回复
-
药学学硕326求调剂
已经有1人回复
-
药理学论文润色/翻译怎么收费?
已经有75人回复
-
华理药学学硕求调剂，总分324
已经有0人回复
-
105500药学调剂，一志愿顶9，主持省级大创，实验型SCI二作，四六级已过，双国奖
已经有6人回复
-
接受药学调剂
已经有11人回复
-
药学专硕调剂
已经有0人回复
-
publcif的使用
已经有0人回复
-
澳门理工大学人工智能药物发现中心招收2026级博士研究生（申请-考核制）
已经有9人回复
-
求调剂
已经有2人回复
-
会计专硕求调剂
已经有0人回复
» 本主题相关价值贴推荐，对您同样有帮助:
- 常见化验项目正常参考值及临床意义-狗和猫
已经有11人回复
- CTD申报资料中 已知杂质结构确证 部分该怎么写呢？
已经有11人回复
- 药理毒理研究资料17-27号资料
已经有6人回复
- 一类新药临床前研究是不是一定要把内毒素降下来
已经有14人回复
- 陨阳医学院临床医学专升本资料
已经有7人回复
- 询问，中药五类新药申报材料中的药学研究资料综述都包括哪些内容
已经有8人回复
- 3.1类新药申报临床8号资料整理，急
已经有15人回复
- 已获临床批件的原进口药品注册申报资料，部分资料英文未翻译，怎么也获批了呢？
已经有6人回复
- 教育部人文社科申报书“前期研究基础及资料准备”能写出自己曾经主持的项目名称不？
已经有4人回复
- 请教教育部人文社科项目的前期研究基础及资料准备怎么写
已经有5人回复
★ ★ ★ ★ ★
caoyuan521(金币+2):谢谢授人以渔！ 2010-11-01 21:19:14
kidant(金币+3):谢谢回帖交流 2010-11-03 09:10:37
caoyuan521(金币+2):谢谢授人以渔！ 2010-11-01 21:19:14
kidant(金币+3):谢谢回帖交流 2010-11-03 09:10:37
|
http://clinicaltrials.gov/ct2/results?term=AC2993 楼主看下这个帖子吧，英语还是自己翻译吧，可以锻炼一下水平，翻译两三次你就都熟悉了！ 希望对你有帮助！ |
3楼2010-11-01 14:27:05
★ ★ ★ ★ ★
kidant(金币+5):谢谢回帖交流 2010-11-03 09:10:28
嘉笛(金币+5): 2010-11-24 10:42:17
kidant(金币+5):谢谢回帖交流 2010-11-03 09:10:28
嘉笛(金币+5): 2010-11-24 10:42:17
|
Evaluation of the Effect on Glucose Control and Safety of AC2993 in Patients With Type 2 Diabetes Treated With Metformin, Sulfonylurea, or Metformin and Sulfonylurea Combination This study has been completed. First Received: September 3, 2002 Last Updated: November 5, 2007 History of Changes Sponsor: Amylin Pharmaceuticals, Inc. Collaborator: Eli Lilly and Company Information provided by: Amylin Pharmaceuticals, Inc. ClinicalTrials.gov Identifier: NCT00044668 Purpose This multi-center, open-label study is designed to examine the effects on long-term glucose control and safety of AC2993 in patients with type 2 diabetes treated with metformin, sulfonylurea, or metformin and sulfonylurea combination. Condition Intervention Phase Diabetes Mellitus, Type 2 Drug: AC2993 (synthetic exendin-4) Phase III Study Type: Interventional Study Design: Allocation: Non-Randomized Control: Uncontrolled Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment Official Title: An Open-Label Study to Examine the Long-Term Effect on Glucose Control (HbA1c) and Safety of AC2993 Given Two Times a Day to Subjects With Type 2 Diabetes Treated With Metformin, a Sulfonylurea, or Metformin and Sulfonylurea Combination Resource links provided by NLM: MedlinePlus related topics: Diabetes Drug Information available for: Exenatide Metformin Metformin hydrochloride U.S. FDA Resources Further study details as provided by Amylin Pharmaceuticals, Inc.: Primary Outcome Measures: •*Examine long-term effect on glucose control of subcutaneously (SC) injected AC2993 administered twice a day (BID) in subjects with type 2 diabetes (T2DM);*Assess long-term safety of SC injected AC2993 administered BID in subjects with T2DM Secondary Outcome Measures: •*Examine long-term effect on various pharmacodynamic measurements of SC injected AC2993 administered BID in subjects with T2DM. Estimated Enrollment: 150 Study Start Date: August 2002 Eligibility Ages Eligible for Study: 20 Years to 75 Years Genders Eligible for Study: Both Accepts Healthy Volunteers: No Criteria Inclusion Criteria: •Subjects with type 2 diabetes •Treated for at least 3 months prior to screening either with metformin, sulfonylurea, or metformin and sulfonylurea combination •BMI 25-45 kg/m^2 •HbA1c between 7.5 % and 12.0 %, inclusive Exclusion Criteria: •Treated with other oral anti-diabetic agents other than metformin and sulfonylureas within 3 months of screening •Patients previously treated with AC2993 •Patients presently treated with insulin Contacts and Locations Please refer to this study by its ClinicalTrials.gov identifier: NCT00044668 Locations Hungary Peterfy Teaching Hospital Budapest, Hungary, H 1076 Diagnostic Units Hungary Kft. Budapest, Hungary, H 1036 Uzsoki Street Municipal Hospital Budapest, Hungary, H 1145 Sponsors and Collaborators Amylin Pharmaceuticals, Inc. Eli Lilly and Company Investigators Study Director: Lisa Porter, MD Amylin Pharmaceuticals, Inc. More Information Additional Information: Link to study results on ClinicalStudyResults.org No publications provided ClinicalTrials.gov Identifier: NCT00044668 History of Changes Other Study ID Numbers: 2993-117 Study First Received: September 3, 2002 Last Updated: November 5, 2007 Health Authority: United States: Food and Drug Administration; Hungary: National Institute of Pharmacy Keywords provided by Amylin Pharmaceuticals, Inc.: exenatide exendin-4 diabetes Amylin Lilly Additional relevant MeSH terms: Diabetes Mellitus Diabetes Mellitus, Type 2 Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Exenatide Metformin Hypoglycemic Agents Physiological Effects of Drugs Pharmacologic Actions |
2楼2010-11-01 14:25:42
quchun12
铜虫 (初入文坛)
- 应助: 0 (幼儿园)
- 金币: 261.5
- 帖子: 30
- 在线: 27.9小时
- 虫号: 1114445
- 注册: 2010-10-05
- 专业: 免疫相关疾病其他科学问题
呢！！ 
4楼2010-11-03 08:44:24
5楼2010-11-03 09:00:41
